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Background: Although most myomas are asymptomatic, quality of life is compromised for many women with
uterine fibroid disease. Twelve-month outcomes from the Halt Trial have been reported in the literature. Here we
analyze the clinical success of radiofrequency volumetric thermal ablation (RFVTA) of symptomatic uterine fibroids
at two years of follow up.
Methods: Prospective, multicenter, outpatient interventional clinical trial of fibroid treatment by RFVTA in 124
premenopausal women (mean age, 42.4 ± 4.4 years) with symptomatic uterine fibroids and objectively confirmed
heavy menstrual bleeding (≥160 to ≤500 mL).
Outcome measures included: subject responses to validated questionnaires, treatment-emergent adverse events,
and surgical re-intervention for fibroids at 24 months postprocedure. Continuous and categorical variables were
summarized using descriptive statistics and means and percentages. Comparisons between visits were based on
t-tests using repeated measures models. P-values < 0.05, adjusted for multiplicity, were statistically significant.
Results: One hundred twelve subjects were followed through 24 months. Change in symptom severity from
baseline was –35.7 (95% CI, –40.1 to –31.4; p<.001). Change in health-related quality of life (HRQL) was 40.9 (95% CI,
36.2 to 45.6; p < .001). HRQL subscores also improved significantly from baseline to 24 months in all categories
(concern, activities, energy/mood, control, self-consciousness, and sexual function) [p<.001]. Six patients underwent
surgical re-intervention for fibroid-related bleeding between 12 and 24 months providing a re-intervention rate of
4.8% (6/124).
Conclusion: Radiofrequency volumetric thermal ablation of myomas significantly reduces symptom severity and
improves quality of life with low surgical re-intervention through 24 months of follow up.
Trial registration: ClinicalTrials.gov: NCT00874029
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Although most uterine fibroids are asymptomatic, heavy
menstrual bleeding presents as the most common com-
plaint among women who undergo myomectomy [1].
For premenopausal women, average menstrual blood
loss is 40 ± 20 mL [2] with monthly bleeding > 60 mL
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reproduction in any medium, provided the oras affecting quality of life [3]. Chudnoff et al reported ef-
ficacy, safety and re-intervention rates up to 12 months
after radiofrequency volumetric thermal ablation (RFVTA)
in 135 women, who had participated in a prospective
multicenter interventional clinical trial for the treat-
ment of uterine myomas and heavy menstrual bleeding
(≥ 160 mL to ≤ 500 mL) [ClinicalTrials.gov Identifier:
NCT00874029] [4]. The RFVTA system delivers mo-
nopolar radiofrequency energy to tissue through a dis-
posable electrosurgical handpiece; the handpiece is
attached to the control unit and is inserted percuta-
neously into the target fibroid tissue [5].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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yond the initial study period of 12 months provides a
realistic assessment of the medium-term efficacy of the
RFVTA treatment. Our objectives were analyses of qua-
litative clinical outcomes, as evidenced by subject res-
ponses to validated questionnaires [6,7], as well as the
incidence of device- and/or procedure-related adverse
events and surgical re-intervention for fibroid treatment
among those subjects followed to 24 months post RFVTA
with the Acessa System (Halt Medical, Inc., Brentwood,
California USA).
Materials and methods
For this prospective, interventional clinical trial
[ClinicalTrials.gov Identifier: NCT00874029], in which
subjects served as their own controls, we recruited and
enrolled premenopausal women with ≤ 6 treatable fibroids
with no single fibroid exceeding 7 cm in any diameter;
these parameters were confirmed by transvaginal ultra-
sound. The subjects’ primary complaint was heavy cyclic
menstrual bleeding (≥ 160 mL to ≤ 500 mL), which was
confirmed by alkaline hematin analysis. For the clinical
trial, the U.S. Food and Drug Administration requiredEnrolled
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Figure 1 Status of study subjects at 24 months post procedure.menstrual blood loss assessment through 12 months of
follow up and suggested quality-of-life assessments there-
after. Recruitment started in February 2009 and enroll-
ment of the last patient was in February of 2011. All
subjects signed informed consent and the 11 clinical sites
in the United States (N = 9) and Latin America (N = 2)
[Appendix A] obtained local institutional review board
(IRB) or independent ethics committee (IEC) approval of
the protocol. The study continues to be conducted in ac-
cordance with the general ethical principles outlined in
the Declaration of Helsinki and applicable local or inter-
national regulations concerning the rights and welfare of
human subjects participating in medical research.
Inclusion criteria for enrolled subjects were premeno-
pausal women of at least 25 years of age, with symptom-
atic uterine fibroids imaged by transvaginal ultrasound
and magnetic resonance imaging, having a uterine size
of ≤ 14 weeks as determined by pelvic examination, a
total fibroid volume of ≤ 300 cm3, a minimum of a
three-month history of heavy menstrual bleeding within
6 months of enrollment and desiring uterine conserva-
tion . Laboratory inclusion criteria were a normal coagu-
lation profile, a normal Papanicolaou test result in theprotocol inclusion/AH parameters
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Table 1 Demographics characteristics of subjects entering
12 months follow up (n = 124)
Variable Statistic/Response a All sites (n = 124)
Age (years) Mean (SD) 42.4 (4.4)
Median 43
Range 31 – 52
Race White or Caucasian 58 (46.8%)
Black or African American 41 (33.1%)
Asian 2 (1.6%)
Other b 23 (18.5%)
Ethnicity Hispanic or Latino 56 (45.2%)
Not Hispanic or Latino 68 (54.8%)
Smoking History Current 25 (20.2%)
Past 21 (16.9%)
Never 78 (62.9%)
Height (cm) Mean (SD) 162.5 (8.1)
Median 162.6
Range 137.2 – 180.3
Weight (kg) Mean (SD) 80.9 (19.4)
Median 79.2
Range 49.0 – 147.4
BMI Mean (SD) 30.5 (6.2)
Median 29.2
Range 19.8 – 47.3
a SD Standard deviation.
b Other, Hispanic, hispanic indigenous, or Caribbean.
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time of treatment. Exclusion criteria were radiologic evi-
dence by magnetic resonance imaging of adenomyosis,
pedunculated intracavitary or subserosal fibroids (pres-
ence of types I and II submucous fibroids were allowed);
history of pelvic malignancy or cervical dysplasia; prior
treatment or removal of fibroids; and women desiring
future childbearing. Any contraindications to abdominal
surgery or to anesthesia excluded enrollment. The treat-
ment was free for all study participants.
Radiofrequency volumetric thermal ablation was per-
formed with the Acessa System, which is comprised of
a dual-function radiofrequency generator, a disposable
3.4-mm handpiece with a deployable seven-needle elec-
trode array and controls for inputting data and modi-
fying generator parameters; two disposable dispersive
electrode pads, which were placed on each thigh; ex-
tension cables; and a foot pedal. A 10-mm or 12-mm
laparoscope was inserted through a 10- or 12-mm um-
bilical trocar, and laparoscopic ultrasound through a
separate 10- or 12-mm trocar (Aloka, Wallingford, CT
USA; BK Medical, Peabody, MA USA) permitted map-
ping of the uterus and identification of the location, size,
and number of all fibroids. The handpiece was inserted
percutaneously (without a trocar) and into the fibroid
using ultrasound guidance and the ablation procedure
was carried out. Details of the procedure and technology
have been presented elsewhere [4,8]. Patients were dis-
charged on the day of treatment after standard postope-
rative care with instructions to return to work and to
normal activities as they felt able and to refrain from
sexual activity for 4–6 weeks. Ibuprofen, naproxen or
celecoxib were prescribed for pain on an as-needed
basis. At each of the follow-up visits (3, 6, 12, and 24
months post procedure), subjects provided written res-
ponses to the validated Uterine Fibroid Symptom and
Quality-of-Life questionnaire (UFS-QOL) [6] and respon-
ded to general health and outcome assessments as mea-
sured by the EuroQol Health State Index, (EQ-5D) [7].
Continuous variables for the analyses performed for
this report were summarized using descriptive statistics,
whereas categorical variables were summarized in terms
of frequencies and percentages. Pairwise comparisons
between the baseline visit and the 3, 6, 12, and 24 month
follow-up visits and pairwise comparisons between each
of the follow-up visits with regard to each UFS-QOL
scale and subscale and the EQ-5D health state scale were
based on t-tests using repeated measures models, where
the scores at each visit were the dependent variables.
Because there were 10 possible pairwise comparisons be-
tween visits for each scale or subscale, p-values were ad-
justed for multiplicity using the Šidák correction; the
adjusted p-values are presented. P-values of < 0.05 were
considered statistically significant.Results
The progression of subjects through their 24-month
visits following RFVTA is presented in Figure 1. Of the
135 women satisfying all inclusion criteria and treated at
baseline, 11 subjects had interfering circumstances unre-
lated to the procedure (pregnancy, lack of menses, and
Hashimoto’s Disease) that could have influenced bleed-
ing assessments positively or negatively. Of the 124 sub-
jects continuing past the 12-month follow up, six sought
surgical re-interventions, one subject became pregnant,
one chose Novasure ablation as diagnostic hysteroscopy
revealed no myomas, and three subjects were lost to fol-
low up or withdrew from the trial. Of the outstanding
113 Uterine Fibroid Symptom and Quality-of-Life ques-
tionnaires, the 11 sites received 112 completed question-
naires. Demographics of those 124 subjects entering the
second year of the study are presented in Table 1.
As shown in Figure 2, patient-reported symptom se-
verity decreased (improved) most readily from baseline
(61.1 ± 18.6) in the first three months of follow up.
Symptom severity scores at 3 months (29.1 ± 18.9), 6
months (28.5 ± 19.3), 12 months (26.6 ± 19.0), and 24
months (25.4 ± 20.6) were similar. The change from the
mean baseline value to that at 24 months for the 112
Figure 2 Mean transformed scores of patient-reported symptom severity and health-related quality of life (UFS-QOL).
Guido et al. Health and Quality of Life Outcomes 2013, 11:139 Page 4 of 8
http://www.hqlo.com/content/11/1/139subjects with baseline and 24-month symptom severity
scores was –35.7 (95% CI, –40.1 to –31.4).
Health-related quality of life also improved most rea-
dily from baseline (37.3 ± 19.1) to 3 months (75.1 ± 22.1).
Successive scores were similar to the 3-month value: 6
months (77.8 ± 20.2), 12 months (79.5 ± 20.6), and 24
months (79.3 ± 21.7). The change at 24 months for the
112 subjects with baseline and 24-month HRQL scores
was 40.9 (95% CI, 36.2 to 45.6).
Patient-reported UFS-QOL subscale scores also im-
proved most readily in the first 3 months of follow up
(Figure 3). Improvement from baseline to 24 months for
each of the subscales is summarized in Table 2. Concern
showed the most improvement (Δ 45.6) and sexual func-
tion, although statistically improved, showed the least
improvement (Δ 29.2) over the study period. These chan-
ges were based on those 112 subjects who had both base-
line and 24-month scores.
Mean health state scores (EQ-5D) improved from
baseline to 3 months and then changed slightly over
time from 85.0 to 84.0 (Figure 4). There was a significant
improvement in the mean health state score between
baseline and 3 months after treatment (p < .001). Mea-
surements at subsequent intervals showed no continuedimprovement, but remained statistically improved over
baseline.
There was one serious adverse event, which occurred
between 12 and 24 months and was possibly related to
the procedure. One subject became pregnant and de-
livered a healthy, full-term baby by Cesarean section.
However, during the Cesarean section, the subject lost
1400–1500 mL of blood. Approximately 48 hours later,
she experienced abdominal pain with additional blood
loss and tissue expulsion. Preliminary pathology indi-
cated degenerative fibroid tissue. The patient received
6 units of blood altogether and was discharged from the
hospital with oral iron therapy for her anemia.
Six patients (6/124, 4.8%) underwent surgical re-
intervention for fibroid-related bleeding between 12 and
24 months (Table 3): 4 hysterectomies and 2 hystero-
scopic myomectomies. Follow-up pathology revealed
multiple small fibroids with adenomyosis in four cases
(patients 1, 3, 4, and 6), and a possible polyp (patient 5).
Pathology studies were not available for Patient 2.
Discussion
The subject device (the Acessa System, Halt Medical, Inc.,
Brentwood, California USA) and the fibroid ablation
Figure 3 Mean transformed scores of patient-reported UFS-QOL subscale scores over time.
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Lee and others specifically for fibroids [5,9]. Despite
resolution of fibroid symptoms achieved in his early
trials using other radiofrequency ablation systems, Lee
found the characteristic bending of the needles an obstacle
to accurate and dependable fibroid ablation. The current
Acessa System and RFVTA procedure showed promise in
feasibility studies carried out in Latin America [8,10] and
proved effective and safe during the first 12 months of fol-
low up in the FDA-approved prospective interventional
clinical trial [4].
This study describes the continued benefits from 12
months [4] through 24 months of follow up; general andTable 2 Improvements in UFS-QOL subscale scores from base
Subscale Baseline 24 months
Concern 24.7 ± 20.7 70.8 ± 28.6
Activities 37.1 ± 24.1 81.1 ± 24.2
Energy/Mood 38.1 ± 21.8 79.3 ± 22.9
Control 45.5 ± 24.9 85.8 ± 22.1
Self-consciousness 38.2 ± 28.3 82.1 ± 21.1
Sexual function 45.5 ± 29.8 74.1 ± 29.1disease-specific quality-of-life outcomes are described.
The UFS-QOL and EQ-5D scales have been validated
and reported as appropriate for use with long-term fol-
low up of patients with symptomatic uterine fibroids
[11]. Coyne et al examined the validity, reliability and re-
sponsiveness of the UFS-QOL scale among women with
symptomatic fibroids through 12 months of follow up
after treatment and among controls (premenopausal
women without fibroids) [12]. The patients in our study
showed significant improvement in their symptom seve-
rity and health-related quality of life from baseline to 3
months post treatment. This was sustained over 2 years,
accompanied by a low rate of re-intervention (4.8%).line to 24 months
Change in score 95% confidence interval
45.6 39.9, 51.3
41.9 37.5, 48.2
39.6 34.6, 44.6
39.1 33.4, 44.9
42.0 36.3, 47.7
29.2 22.7, 35.8
Figure 4 Mean health state (EQ-5D) scores over time.
Table 3 Surgical re-interventions (6/124, 4.8%) between 12 and 24 months post procedure
Pt Treated fibroidsa Symp severityb HRQLc Reintervention Pathology
Baseline 12 mo Baseline 12 mo
1 6 Subserosals 5.6; 4.4; 1.5;
3.6; 1.9; 3.0
53.1 28.1 46.6 89.7 Hysterectomy at 16.5 months Multiple myomas ranging from
0.4 to 4.7 cm; focally irregular
endo-myometrial junction
2 Intramurals 4.8: 4.7
1 Subserosal/Intramural 2.7
2 4 Intramurals 5.2; 1.8; 1.1; 1.8 68.8 28.1 10.3 82.8 Hysteroscopic myomectomy
by resection at 15 months
No pathology
3 3 Subserosals 5.0; 1.3; 1.9 78.1 43.8 20.7 51.7 Hysterectomy at 14 months Multiple myomas ranging from 0.6
to 3.4 cm; focal adenomyosis
1 Intramural 1.8
4 1 Intramural 2.0 62.5 28.1 10.3 60.3 Supracervical hysterectomy at
23 months
Only morcellated tissue available.
Findings: adenomyosis, leiomyomata,
proliferative endometrium1 Submucosal 2.0 1
Undefined 1.9
5 5 Intramurals 2.7; 2.7; 2.6;
8.5; 6.7
75.0 56.3 17.2 28.4 Hysteroscopic myomectomy
by resection at 16 months
Focal degenerative changes and
features suggestive of polyp
1 Undefined 3.2
6 1 Intramural 2.0 53.1 62.5 37.1 43.1 Hysterectomy at 23.5 months Adenomyosis; multiple myomas ranging
in size from 0.4 cm to 1.2 cm
1 Subserosal 2.0
a Information includes the number of each type of treated fibroid and the maximum diameter (cm) of each fibroid.
b Mean transformed symptom severity scores.
c Mean transformed health-related quality-of-life scores.
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term (≥ 2 years) results. Some patients, who did not
improve at 3 months, showed improvement at later
follow-up periods. Continued follow up to 36 months is
planned. Researchers of other fibroid treatments have
reported similar improvements in symptom severity and
quality of life but with re-intervention rates after two-to-
three years nearing 26% [10,13,14].
The introduction of new technologies in gynecology
has increased women’s options for the treatment of
benign gynecologic conditions. These include the use
of global endometrial ablation as an alternative to
hysterectomies, especially for those women with ab-
normal bleeding and adenomyosis, and the use of
uterine fibroid embolization for the treatment of fi-
broids. However, it is important to track the outcomes
of new procedures to confirm the durability of the
treatment.
Conclusions
Radiofrequency volumetric thermal ablation broadly met
the needs of the study patients. The low adverse event
and re-intervention rates through 24 months are positive
outcomes for patient wellbeing and demonstrate that the
improvement in symptoms and the increase in the pa-
tients’ quality of life are durable for at least a period
of 2 years.
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